Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDV-plasmid-spike-GC COVID-19 vaccine Phase 1/2a study
ACTRN12621001159842Phase 2Recruiting
- Sponsor
- EnGeneIC
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of COVID-19-EDV in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by EnGeneIC. Primary endpoints: Safety and tolerability of EDV-plasmid-spike-GC and Composite immune response. Started Aug 2021; status: recruiting.
02
Drugs
COVID-19-EDV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12621001159842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001159842.